Utility of serum antibodies in determining clinical course in pediatric Crohn's disease

Barbara Desir, Devendra K. Amre, Shou En Lu, Pamela Ohman-Strickland, Marla Dubinsky, Rachel Fisher, Ernest G. Seidman

Research output: Contribution to journalArticle

Abstract

Background & Aims: The utility of serial measurements of anti-Saccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies in Crohn's disease (CD) evolution is unknown. We aimed to study the pattern of antibody change and the prognosis of selected outcomes by baseline (at time of diagnosis) and serial antibody measurements in pediatric CD patients. Methods: Serum ASCA and p-ANCA antibodies were measured at baseline (n = 154) and repeated during follow-up (n = 61) using standard techniques in a cohort of patients identified at Hôpital Sainte-Justine between 1996 and 1998. Clinical information was abstracted from medical charts. Antibody patterns were examined using mixed modeling techniques. The prognostic ability of antibodies for selected outcomes was evaluated using logistic regression. Results: Fifteen (24.5%), 18 (29.5%), and 11 (18%) patients with serial antibody measurements changed their ASCA-IgA, ASCA-IgG, and p-ANCA status (positivity), respectively. No distinct patterns in the evolution of antibody titers were noted. Baseline ASCA-IgA positivity significantly predicted relapses during disease course (IgA: odds ratio [OR], 2.9; 95% confidence interval [CI], 1.33-6.35). Serial antibody measurements did not predict the occurrence of clinical outcomes. Conclusions: Baseline serum antibodies were predictive of a more relapsing disease course in pediatric CD. However, the limited variability in the antibodies over time and the inability of serial measurements to predict clinical outcomes may limit their use in the establishment of intervention strategies.

Original languageEnglish (US)
Pages (from-to)139-146
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume2
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Antibodies
Serum
Saccharomyces cerevisiae
Antineutrophil Cytoplasmic Antibodies
Immunoglobulin A
Pediatric Crohn's disease
Crohn Disease
Immunoglobulin G
Logistic Models
Odds Ratio
Confidence Intervals
Recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Desir, B., Amre, D. K., Lu, S. E., Ohman-Strickland, P., Dubinsky, M., Fisher, R., & Seidman, E. G. (2004). Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clinical Gastroenterology and Hepatology, 2(2), 139-146. https://doi.org/10.1016/S1542-3565(03)00321-5

Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. / Desir, Barbara; Amre, Devendra K.; Lu, Shou En; Ohman-Strickland, Pamela; Dubinsky, Marla; Fisher, Rachel; Seidman, Ernest G.

In: Clinical Gastroenterology and Hepatology, Vol. 2, No. 2, 02.2004, p. 139-146.

Research output: Contribution to journalArticle

Desir, B, Amre, DK, Lu, SE, Ohman-Strickland, P, Dubinsky, M, Fisher, R & Seidman, EG 2004, 'Utility of serum antibodies in determining clinical course in pediatric Crohn's disease', Clinical Gastroenterology and Hepatology, vol. 2, no. 2, pp. 139-146. https://doi.org/10.1016/S1542-3565(03)00321-5
Desir, Barbara ; Amre, Devendra K. ; Lu, Shou En ; Ohman-Strickland, Pamela ; Dubinsky, Marla ; Fisher, Rachel ; Seidman, Ernest G. / Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. In: Clinical Gastroenterology and Hepatology. 2004 ; Vol. 2, No. 2. pp. 139-146.
@article{51edda10a26c4f28afe4e1e186e6d256,
title = "Utility of serum antibodies in determining clinical course in pediatric Crohn's disease",
abstract = "Background & Aims: The utility of serial measurements of anti-Saccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies in Crohn's disease (CD) evolution is unknown. We aimed to study the pattern of antibody change and the prognosis of selected outcomes by baseline (at time of diagnosis) and serial antibody measurements in pediatric CD patients. Methods: Serum ASCA and p-ANCA antibodies were measured at baseline (n = 154) and repeated during follow-up (n = 61) using standard techniques in a cohort of patients identified at H{\^o}pital Sainte-Justine between 1996 and 1998. Clinical information was abstracted from medical charts. Antibody patterns were examined using mixed modeling techniques. The prognostic ability of antibodies for selected outcomes was evaluated using logistic regression. Results: Fifteen (24.5{\%}), 18 (29.5{\%}), and 11 (18{\%}) patients with serial antibody measurements changed their ASCA-IgA, ASCA-IgG, and p-ANCA status (positivity), respectively. No distinct patterns in the evolution of antibody titers were noted. Baseline ASCA-IgA positivity significantly predicted relapses during disease course (IgA: odds ratio [OR], 2.9; 95{\%} confidence interval [CI], 1.33-6.35). Serial antibody measurements did not predict the occurrence of clinical outcomes. Conclusions: Baseline serum antibodies were predictive of a more relapsing disease course in pediatric CD. However, the limited variability in the antibodies over time and the inability of serial measurements to predict clinical outcomes may limit their use in the establishment of intervention strategies.",
author = "Barbara Desir and Amre, {Devendra K.} and Lu, {Shou En} and Pamela Ohman-Strickland and Marla Dubinsky and Rachel Fisher and Seidman, {Ernest G.}",
year = "2004",
month = "2",
doi = "10.1016/S1542-3565(03)00321-5",
language = "English (US)",
volume = "2",
pages = "139--146",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Utility of serum antibodies in determining clinical course in pediatric Crohn's disease

AU - Desir, Barbara

AU - Amre, Devendra K.

AU - Lu, Shou En

AU - Ohman-Strickland, Pamela

AU - Dubinsky, Marla

AU - Fisher, Rachel

AU - Seidman, Ernest G.

PY - 2004/2

Y1 - 2004/2

N2 - Background & Aims: The utility of serial measurements of anti-Saccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies in Crohn's disease (CD) evolution is unknown. We aimed to study the pattern of antibody change and the prognosis of selected outcomes by baseline (at time of diagnosis) and serial antibody measurements in pediatric CD patients. Methods: Serum ASCA and p-ANCA antibodies were measured at baseline (n = 154) and repeated during follow-up (n = 61) using standard techniques in a cohort of patients identified at Hôpital Sainte-Justine between 1996 and 1998. Clinical information was abstracted from medical charts. Antibody patterns were examined using mixed modeling techniques. The prognostic ability of antibodies for selected outcomes was evaluated using logistic regression. Results: Fifteen (24.5%), 18 (29.5%), and 11 (18%) patients with serial antibody measurements changed their ASCA-IgA, ASCA-IgG, and p-ANCA status (positivity), respectively. No distinct patterns in the evolution of antibody titers were noted. Baseline ASCA-IgA positivity significantly predicted relapses during disease course (IgA: odds ratio [OR], 2.9; 95% confidence interval [CI], 1.33-6.35). Serial antibody measurements did not predict the occurrence of clinical outcomes. Conclusions: Baseline serum antibodies were predictive of a more relapsing disease course in pediatric CD. However, the limited variability in the antibodies over time and the inability of serial measurements to predict clinical outcomes may limit their use in the establishment of intervention strategies.

AB - Background & Aims: The utility of serial measurements of anti-Saccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies in Crohn's disease (CD) evolution is unknown. We aimed to study the pattern of antibody change and the prognosis of selected outcomes by baseline (at time of diagnosis) and serial antibody measurements in pediatric CD patients. Methods: Serum ASCA and p-ANCA antibodies were measured at baseline (n = 154) and repeated during follow-up (n = 61) using standard techniques in a cohort of patients identified at Hôpital Sainte-Justine between 1996 and 1998. Clinical information was abstracted from medical charts. Antibody patterns were examined using mixed modeling techniques. The prognostic ability of antibodies for selected outcomes was evaluated using logistic regression. Results: Fifteen (24.5%), 18 (29.5%), and 11 (18%) patients with serial antibody measurements changed their ASCA-IgA, ASCA-IgG, and p-ANCA status (positivity), respectively. No distinct patterns in the evolution of antibody titers were noted. Baseline ASCA-IgA positivity significantly predicted relapses during disease course (IgA: odds ratio [OR], 2.9; 95% confidence interval [CI], 1.33-6.35). Serial antibody measurements did not predict the occurrence of clinical outcomes. Conclusions: Baseline serum antibodies were predictive of a more relapsing disease course in pediatric CD. However, the limited variability in the antibodies over time and the inability of serial measurements to predict clinical outcomes may limit their use in the establishment of intervention strategies.

UR - http://www.scopus.com/inward/record.url?scp=0842304879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842304879&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(03)00321-5

DO - 10.1016/S1542-3565(03)00321-5

M3 - Article

VL - 2

SP - 139

EP - 146

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -